These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38558508)

  • 21. Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes.
    Home P; Derwahl KM; Ziemen M; Wernicke-Panten K; Pierre S; Kirchhein Y; Garg SK
    Diabetes Technol Ther; 2018 Feb; 20(2):160-170. PubMed ID: 29355435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
    Garg SK; Wernicke-Panten K; Rojeski M; Pierre S; Kirchhein Y; Jedynasty K
    Diabetes Technol Ther; 2017 Sep; 19(9):516-526. PubMed ID: 28722480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union].
    Altman JJ; Chevalier N; Delemer B; Travert F; Benabbad I
    Presse Med; 2018 Oct; 47(10):854-866. PubMed ID: 30262205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYL1501D Insulin Glargine: A Review in Diabetes Mellitus.
    Hoy SM
    BioDrugs; 2020 Apr; 34(2):245-251. PubMed ID: 32215829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins.
    Chen W; Lu J; Plum-Mörschel L; Andersen G; Zijlstra E; He A; Xie T; Li L; Hao C; Gan Z; Heise T
    Diabetes Obes Metab; 2023 Dec; 25(12):3817-3825. PubMed ID: 37735841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In brief: Semglee - insulin glargine interchangeable with Lantus.
    Med Lett Drugs Ther; 2021 Oct; 63(1634):159-160. PubMed ID: 34550958
    [No Abstract]   [Full Text] [Related]  

  • 27. Real-World Impact of Switching From Insulin Glargine (Lantus
    AlRuthia Y; Bahari OH; Alghnam S; Alrumaih AM; Asiri H; Alshammari M; Alhowimel M; Al-Abdulkarim HA
    Front Public Health; 2022; 10():852721. PubMed ID: 35769787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lilly Insulin Glargine Versus Lantus
    Mohan V; Ahn KJ; Cho YM; Sahay RK; Huang CN; Kalra S; Chadha M; Bhattacharya I; Kim SY; Spaepen E
    Clin Drug Investig; 2019 Aug; 39(8):745-756. PubMed ID: 31119716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study.
    Derwahl KM; Bailey TS; Wernicke-Panten K; Ping L; Pierre S
    Diabetes Technol Ther; 2018 Jan; 20(1):49-58. PubMed ID: 29232162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus
    Karonova TL; Mosikian AA; Mayorov AY; Makarenko IE; Zyangirova ST; Afonkina OA; Belikova TM; Zalevskaya AG; Khokhlov AL; Drai RV
    J Comp Eff Res; 2020 Mar; 9(4):263-273. PubMed ID: 32027167
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
    Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
    JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.
    Sun B; Sengupta N; Rao A; Donnelly C; Waichale V; Roy AS; Ramaswamy S; Pathak D; Bowsher RR; Raiter Y; Aubonnet P; Barve A
    BMC Endocr Disord; 2021 Jun; 21(1):129. PubMed ID: 34174848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilar vs originator insulins: Systematic review and meta-analysis.
    Yamada T; Kamata R; Ishinohachi K; Shojima N; Ananiadou S; Nom H; Yamauchi T; Kadowaki T
    Diabetes Obes Metab; 2018 Jul; 20(7):1787-1792. PubMed ID: 29536603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    Rosenstock J; Bain SC; Gowda A; Jódar E; Liang B; Lingvay I; Nishida T; Trevisan R; Mosenzon O;
    N Engl J Med; 2023 Jul; 389(4):297-308. PubMed ID: 37356066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial.
    Feng W; Chen W; Jiang S; Du L; Zhu D
    Diabetes Obes Metab; 2021 Aug; 23(8):1786-1794. PubMed ID: 33783964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
    Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
    N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial.
    Yan X; Jiang S; Lou Y; Zhou Z
    Diabetes Obes Metab; 2021 Oct; 23(10):2226-2233. PubMed ID: 34121308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.